Skip to main content
Erschienen in: Neurocritical Care 1/2012

01.08.2012 | Letter to the Editor

The Slippery Slope of Platelet Transfusion for Intracerebral Hemorrhage

verfasst von: Wendy C. Ziai, Marek A. Mirski

Erschienen in: Neurocritical Care | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …
Literatur
1.
Zurück zum Zitat Ziai WC, Torbey MT, Kickler TS, Oh S, Bhardwaj A, Wityk RJ. Platelet count and function in spontaneous intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2003;12:201–6.PubMedCrossRef Ziai WC, Torbey MT, Kickler TS, Oh S, Bhardwaj A, Wityk RJ. Platelet count and function in spontaneous intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2003;12:201–6.PubMedCrossRef
2.
Zurück zum Zitat Akins PT, Guppy KH, Sahrakar K, Hawk MW. Slippery platelet syndromes in subdural hematoma. Neurocrit Care. 2010;12:375–81.PubMedCrossRef Akins PT, Guppy KH, Sahrakar K, Hawk MW. Slippery platelet syndromes in subdural hematoma. Neurocrit Care. 2010;12:375–81.PubMedCrossRef
3.
Zurück zum Zitat Naidech AM, Bernstein RA, Levasseur K, Bassin SL, Bendok BR, Batjer HH, et al. Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol. 2009;65:352–6.PubMedCrossRef Naidech AM, Bernstein RA, Levasseur K, Bassin SL, Bendok BR, Batjer HH, et al. Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol. 2009;65:352–6.PubMedCrossRef
4.
Zurück zum Zitat Naidech AM, Bassin SL, Bernstein RA, Batjer HH, Alberts MJ, Lindholm PF, et al. Reduced platelet activity is more common than reported anti-platelet medication use in patients with intracerebral hemorrhage. Neurocrit Care. 2009;11:307–10.PubMedCrossRef Naidech AM, Bassin SL, Bernstein RA, Batjer HH, Alberts MJ, Lindholm PF, et al. Reduced platelet activity is more common than reported anti-platelet medication use in patients with intracerebral hemorrhage. Neurocrit Care. 2009;11:307–10.PubMedCrossRef
5.
Zurück zum Zitat Roquer J, Rodriguez-Compello A, Gomis M, Ois A, Munteis E. Previous anti-platelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol. 2005;252:412–6.PubMedCrossRef Roquer J, Rodriguez-Compello A, Gomis M, Ois A, Munteis E. Previous anti-platelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol. 2005;252:412–6.PubMedCrossRef
6.
Zurück zum Zitat Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen E, Hillborm M. Regular aspirin use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006;37:129–33.PubMedCrossRef Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen E, Hillborm M. Regular aspirin use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006;37:129–33.PubMedCrossRef
7.
Zurück zum Zitat Thompson BB, Bejot Y, Caso V, Castillo J, Christensen H, Flaherty ML, Foerch C, Ghandehari K, Giroud M, Greenberg SM, Hallevi H, Hemphill JC 3rd, Heuschmann P, Juvela S, Kimura K, Myint PK, Nagakane Y, Naritomi H, Passero S, Rodriguez-Yanez MR, Roquer J, Rosand J, Rost NS, Saloheimo P, Salomaa V, Sivenius J, Sorimachi T, Togha M, Toyoda K, Turaj W, Vemmos KN, Wolfe CD, Woo D, Smith EE. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology. 2010;75:1333–42.PubMedCrossRef Thompson BB, Bejot Y, Caso V, Castillo J, Christensen H, Flaherty ML, Foerch C, Ghandehari K, Giroud M, Greenberg SM, Hallevi H, Hemphill JC 3rd, Heuschmann P, Juvela S, Kimura K, Myint PK, Nagakane Y, Naritomi H, Passero S, Rodriguez-Yanez MR, Roquer J, Rosand J, Rost NS, Saloheimo P, Salomaa V, Sivenius J, Sorimachi T, Togha M, Toyoda K, Turaj W, Vemmos KN, Wolfe CD, Woo D, Smith EE. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology. 2010;75:1333–42.PubMedCrossRef
8.
Zurück zum Zitat Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok BR, Bernstein RA, Alberts MJ, Batjer HH. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009;40:2398–401.PubMedCrossRef Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok BR, Bernstein RA, Alberts MJ, Batjer HH. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009;40:2398–401.PubMedCrossRef
9.
Zurück zum Zitat Naidech AM, Bendok BR, Garg RK, Bernstein RA, Alberts MJ, Bleck TP, et al. Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery. 2009;65:684–8. discussion 688.PubMedCrossRef Naidech AM, Bendok BR, Garg RK, Bernstein RA, Alberts MJ, Bleck TP, et al. Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery. 2009;65:684–8. discussion 688.PubMedCrossRef
10.
Zurück zum Zitat Creutzfeldt CJ, Weinstein JR, Longstreth WT Jr, Becker KJ, McPharlin TO, Tirschwell DL. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2009;18:221–8.PubMedCrossRef Creutzfeldt CJ, Weinstein JR, Longstreth WT Jr, Becker KJ, McPharlin TO, Tirschwell DL. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2009;18:221–8.PubMedCrossRef
11.
Zurück zum Zitat Lauer A, Schlunk F, Van Cott EM, Steinmetz H, Lo EH, Foerch C. Antiplatelet pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage. J Cereb Blood Flow Metab. 2011;31(8):1736–42.PubMedCrossRef Lauer A, Schlunk F, Van Cott EM, Steinmetz H, Lo EH, Foerch C. Antiplatelet pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage. J Cereb Blood Flow Metab. 2011;31(8):1736–42.PubMedCrossRef
12.
Zurück zum Zitat Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J. Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review. World Neurosurg. 2010;74:279–85.PubMedCrossRef Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J. Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review. World Neurosurg. 2010;74:279–85.PubMedCrossRef
13.
Zurück zum Zitat Naidech AM, Liebling SM, Rosenberg NF, Lindholm PF, Bernstein RA, Batjer HH, Alberts MJ, Kwaan HC. Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. Neurocrit Care. 2012;16(1):82–7.PubMedCrossRef Naidech AM, Liebling SM, Rosenberg NF, Lindholm PF, Bernstein RA, Batjer HH, Alberts MJ, Kwaan HC. Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. Neurocrit Care. 2012;16(1):82–7.PubMedCrossRef
14.
Zurück zum Zitat Heddle NM, Webert KE. Investigation of acute transfusion reactions. In: Murphy MF, Pamphilon DH, editors. Practical transfusion medicine. 3rd ed. Oxford: Wiley-Blackwell; 2009. p. 63–89. Heddle NM, Webert KE. Investigation of acute transfusion reactions. In: Murphy MF, Pamphilon DH, editors. Practical transfusion medicine. 3rd ed. Oxford: Wiley-Blackwell; 2009. p. 63–89.
15.
Zurück zum Zitat Shaz BH, Stowell SR, Hillyer CD. Transfusion-related acute lung injury: from bedside to bench and back. Blood. 2011;117(5):1463–71.PubMedCrossRef Shaz BH, Stowell SR, Hillyer CD. Transfusion-related acute lung injury: from bedside to bench and back. Blood. 2011;117(5):1463–71.PubMedCrossRef
16.
Zurück zum Zitat Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP. The platelet as an immune cell—CD40 ligand and transfusion immunomodulation. Immunol Res. 2009;45:251–60.CrossRef Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP. The platelet as an immune cell—CD40 ligand and transfusion immunomodulation. Immunol Res. 2009;45:251–60.CrossRef
17.
Zurück zum Zitat Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ. Transfusion-related acute lung injury surveillance (2003–2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion. 2007;47:599–607.PubMedCrossRef Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ. Transfusion-related acute lung injury surveillance (2003–2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion. 2007;47:599–607.PubMedCrossRef
18.
Zurück zum Zitat Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM, on behalf of the Serious Hazards of Transfusion Steering Group. Ten years of haemovigilance reports of transfusion related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49:440–52.PubMedCrossRef Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM, on behalf of the Serious Hazards of Transfusion Steering Group. Ten years of haemovigilance reports of transfusion related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49:440–52.PubMedCrossRef
Metadaten
Titel
The Slippery Slope of Platelet Transfusion for Intracerebral Hemorrhage
verfasst von
Wendy C. Ziai
Marek A. Mirski
Publikationsdatum
01.08.2012
Verlag
Humana Press Inc
Erschienen in
Neurocritical Care / Ausgabe 1/2012
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-012-9694-0

Weitere Artikel der Ausgabe 1/2012

Neurocritical Care 1/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.